Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations
November 16 2016 - 5:00PM
Business Wire
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the
promotion of James R. Meyers to Executive Vice President, Worldwide
Commercial Operations, with responsibility for commercial
operations in North America, Europe and Japan. Mr. Meyers will
become an officer of the company and member of Gilead’s senior
leadership team.
Mr. Meyers joined Gilead in 1996 as a regional sales director
and has been the Senior Vice President of North American Commercial
Operations since 2007. In his 20 years at Gilead, Mr. Meyers has
been instrumental in building out the company’s commercial
operations in North America, including leading successful product
launches in HIV, oncology, cardiovascular, respiratory and liver
diseases. Prior to Gilead, Mr. Meyers held positions of increasing
responsibility in sales, training, marketing and management with
Zeneca Pharmaceuticals and Astra USA. He received his Bachelor's
degree in economics from Boston College.
“Jim has demonstrated a remarkable ability to navigate the
complexities of commercial operations, ensuring we reach diverse
audiences with information about Gilead’s medicines and ultimately
that we make those medicines accessible to people in need,” said
Kevin Young CBE, Chief Operating Officer, Gilead Sciences. “I am
confident that as Gilead’s portfolio of products continues to grow,
Jim’s leadership and exceptional track record make him ideally
suited to lead our global commercial organization.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
Gilead Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors. These
risks, uncertainties and other factors could cause actual results
to differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2016, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-650-574-3000.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161116006551/en/
Gilead Sciences, Inc.InvestorsSung Lee, 650-524-7792MediaAmy
Flood, 650-522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024